{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:42:17Z","timestamp":1740163337171,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004166","name":"Warszawski Uniwersytet Medyczny","doi-asserted-by":"publisher","award":["1M4\/1\/PUR\/N\/21"],"award-info":[{"award-number":["1M4\/1\/PUR\/N\/21"]}],"id":[{"id":"10.13039\/501100004166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s13555-021-00667-w","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T17:02:26Z","timestamp":1643216546000},"page":"599-604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lentigo Maligna on a Difficult Location of the Face Treated with 5% Imiquimod: A Case Report of 2-Year Follow-Up"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7638-9719","authenticated-orcid":false,"given":"Magdalena","family":"Misiak-Galazka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Czuwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Galazka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czaplicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lidia","family":"Rudnicka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2147\/CCID.S224738","volume":"13","author":"H Iznardo","year":"2020","unstructured":"Iznardo H, Garcia-Melendo C, Y\u00e9lamos O. Lentigo maligna: clinical presentation and appropriate management. Clin Cosmet Investig Dermatol. 2020;13:837\u201355.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"667_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaad.2018.08.055","volume":"80","author":"SM Swetter","year":"2019","unstructured":"Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol. 2019;80:208\u201350.","journal-title":"J Am Acad Dermatol"},{"key":"667_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1001\/archdermatol.2012.270","volume":"148","author":"MA Hyde","year":"2012","unstructured":"Hyde MA, Hadley ML, Tristani-Firouzi P, Goldgar D, Bowen GM. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. Arch Dermatol. 2012;148:592\u20136.","journal-title":"Arch Dermatol"},{"key":"667_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/CMR.0000000000000619","volume":"30","author":"SW Menzies","year":"2020","unstructured":"Menzies SW, Liyanarachchi S, Coates E, et al. Estimated risk of progression of lentigo maligna to lentigo maligna melanoma. Melanoma Res. 2020;30:193\u20137.","journal-title":"Melanoma Res"},{"key":"667_CR5","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1111\/bjd.20407","volume":"185","author":"A Lallas","year":"2021","unstructured":"Lallas A, Moscarella E, Kittler H, et al. Real-world experience of off-label use of imiquimod 5% as an adjuvant therapy after surgery or as a monotherapy for lentigo maligna. Br J Dermatol. 2021;185:675\u20137.","journal-title":"Br J Dermatol"},{"key":"667_CR6","doi-asserted-by":"publisher","first-page":"884","DOI":"10.2340\/00015555-3241","volume":"99","author":"D Tio","year":"2019","unstructured":"Tio D, van Montfrans C, Ruijter CGH, Hoekzema R, Bekkenk MW. Effectiveness of 5% topical imiquimod for lentigo maligna treatment. Acta Derm Venereol. 2019;99:884\u20138.","journal-title":"Acta Derm Venereol"},{"key":"667_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2340\/00015555-1861","volume":"95","author":"G Kirtschig","year":"2015","unstructured":"Kirtschig G, van Meurs T, van Doorn R. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. Acta Derm Venereol. 2015;95:83\u20135.","journal-title":"Acta Derm Venereol"},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2015.05.022","volume":"73","author":"AN Mora","year":"2015","unstructured":"Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. J Am Acad Dermatol. 2015;73:205\u201312.","journal-title":"J Am Acad Dermatol"},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/jdv.14085","volume":"31","author":"D Tio","year":"2017","unstructured":"Tio D, van der Woude J, Prinsen CAC, Jansma EP, Hoekzema R, van Montfrans C. A systematic review on the role of imiquimod in lentigo maligna and lentigo maligna melanoma: need for standardization of treatment schedule and outcome measures. J Eur Acad Dermatol Venereol. 2017;31:616\u201324.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 2","key":"667_CR10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2133.2007.08265.x","volume":"157","author":"MP Sch\u00f6n","year":"2007","unstructured":"Sch\u00f6n MP, Sch\u00f6n M. Imiquimod: mode of action. Br J Dermatol. 2007;157(Suppl 2):8\u201313.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-021-00667-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-021-00667-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:18:15Z","timestamp":1645067895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-021-00667-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s13555-021-00667-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"type":"print","value":"2193-8210"},{"type":"electronic","value":"2190-9172"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"25 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}